196 related articles for article (PubMed ID: 20818175)
21. Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization.
Del Pozo Martin Y; Park D; Ramachandran A; Ombrato L; Calvo F; Chakravarty P; Spencer-Dene B; Derzsi S; Hill CS; Sahai E; Malanchi I
Cell Rep; 2015 Dec; 13(11):2456-2469. PubMed ID: 26670048
[TBL] [Abstract][Full Text] [Related]
22. The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia.
Venkitachalam S; Babu D; Ravillah D; Katabathula RM; Joseph P; Singh S; Udhayakumar B; Miao Y; Martinez-Uribe O; Hogue JA; Kresak AM; Dawson D; LaFramboise T; Willis JE; Chak A; Garman KS; Blum AE; Varadan V; Guda K
Gastroenterology; 2022 Nov; 163(5):1228-1241. PubMed ID: 35870513
[TBL] [Abstract][Full Text] [Related]
23. In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development.
Yin H; Hua Y; Feng S; Xu Y; Ding Y; Liu S; Chen D; Du F; Liang G; Zhan W; Shen Y
Adv Mater; 2024 May; 36(21):e2308504. PubMed ID: 38546279
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines.
Hartmans E; Linssen MD; Sikkens C; Levens A; Witjes MJH; van Dam GM; Nagengast WB
Oncotarget; 2017 May; 8(18):29846-29856. PubMed ID: 28415738
[TBL] [Abstract][Full Text] [Related]
25. ANPEP/CD13 Expression as a Marker of Lymphovascular Invasion and Survival in Esophageal Adenocarcinoma.
Goltsov AA; Maru DM; Katkhuda R; Duose DY; Luthra R; Correa AM; Wang F; Futreal PA; Hofstetter WL
Ann Thorac Surg; 2024 Jul; 118(1):241-251. PubMed ID: 37806335
[TBL] [Abstract][Full Text] [Related]
26. p85β regulates autophagic degradation of AXL to activate oncogenic signaling.
Rao L; Mak VCY; Zhou Y; Zhang D; Li X; Fung CCY; Sharma R; Gu C; Lu Y; Tipoe GL; Cheung ANY; Mills GB; Cheung LWT
Nat Commun; 2020 May; 11(1):2291. PubMed ID: 32385243
[TBL] [Abstract][Full Text] [Related]
27. Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma.
Chen L; Lu H; Peng D; Cao LL; Ballout F; Srirmajayam K; Chen Z; Bhat A; Wang TC; Capobianco A; Que J; McDonald OG; Zaika A; Zhang S; El-Rifai W
Gut; 2023 Mar; 72(3):421-432. PubMed ID: 35750470
[TBL] [Abstract][Full Text] [Related]
28. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
Commun Biol; 2023 Jun; 6(1):660. PubMed ID: 37349576
[TBL] [Abstract][Full Text] [Related]
29. Plant growth regulators and Axl and immune checkpoint inhibitors from the edible mushroom
Malya IY; Wu J; Harada E; Toda M; D'Alessandro-Gabazza CN; Yasuma T; Gabazza EC; Choi JH; Hirai H; Kawagishi H
Biosci Biotechnol Biochem; 2020 Jul; 84(7):1332-1338. PubMed ID: 32200702
[TBL] [Abstract][Full Text] [Related]
30. miRNA profiling of esophageal adenocarcinoma using transcriptome analysis.
Corlett R; Button C; Scheel S; Agrawal S; Rai V; Nandipati KC
Cancer Biomark; 2024; 39(3):245-264. PubMed ID: 38250763
[TBL] [Abstract][Full Text] [Related]
31. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition.
Pinato DJ; Chowdhury S; Stebbing J
Oncogene; 2016 May; 35(21):2684-6. PubMed ID: 26434595
[TBL] [Abstract][Full Text] [Related]
32. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
[TBL] [Abstract][Full Text] [Related]
33. High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery.
Hughes RE; Elliott RJR; Munro AF; Makda A; O'Neill JR; Hupp T; Carragher NO
SLAS Discov; 2020 Aug; 25(7):770-782. PubMed ID: 32441181
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profiling identifies divergent chemosensitivities of differentiating and maturing iPSC-derived human cortical neuron populations.
Sharlow ER; Llaneza DC; Tewari BP; Mingledorff GA; Mendelson AJ; Sontheimer H; Bloom GS; Lazo JS
FEBS J; 2023 Oct; 290(20):4950-4965. PubMed ID: 37428551
[TBL] [Abstract][Full Text] [Related]
35. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.
Li X; Francies HE; Secrier M; Perner J; Miremadi A; Galeano-Dalmau N; Barendt WJ; Letchford L; Leyden GM; Goffin EK; Barthorpe A; Lightfoot H; Chen E; Gilbert J; Noorani A; Devonshire G; Bower L; Grantham A; MacRae S; Grehan N; Wedge DC; Fitzgerald RC; Garnett MJ
Nat Commun; 2018 Jul; 9(1):2983. PubMed ID: 30061675
[TBL] [Abstract][Full Text] [Related]
36. Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets.
Cruz-Acuña R; Kariuki SW; Sugiura K; Karaiskos S; Plaster EM; Loebel C; Efe G; Karakasheva T; Gabre JT; Hu J; Burdick JA; Rustgi AK
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37788109
[TBL] [Abstract][Full Text] [Related]
37. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Secrier M; Li X; de Silva N; Eldridge MD; Contino G; Bornschein J; MacRae S; Grehan N; O'Donovan M; Miremadi A; Yang TP; Bower L; Chettouh H; Crawte J; Galeano-Dalmau N; Grabowska A; Saunders J; Underwood T; Waddell N; Barbour AP; Nutzinger B; Achilleos A; Edwards PA; Lynch AG; Tavaré S; Fitzgerald RC;
Nat Genet; 2016 Oct; 48(10):1131-41. PubMed ID: 27595477
[TBL] [Abstract][Full Text] [Related]
38. Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations.
Creixell M; Taylor SD; Gerritsen J; Bae SY; Jiang M; Augustin T; Loui M; Boixo C; Creixell P; White FM; Meyer AS
bioRxiv; 2023 Oct; ():. PubMed ID: 37961516
[TBL] [Abstract][Full Text] [Related]
39. Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.
Contino G; Eldridge MD; Secrier M; Bower L; Fels Elliott R; Weaver J; Lynch AG; Edwards PA; Fitzgerald RC
F1000Res; 2016; 5():1336. PubMed ID: 27594985
[TBL] [Abstract][Full Text] [Related]
40. Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation.
O'Neill JR; Yébenes Mayordomo M; Mitulović G; Al Shboul S; Bedran G; Faktor J; Hernychova L; Uhrik L; Gómez-Herranz M; Kocikowski M; Save V; Vojtěšek B; Arends MJ; ; Hupp T; Alfaro JA
Mol Cell Proteomics; 2024 Apr; 23(6):100764. PubMed ID: 38604503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
